Review: SSRI use ups risk of upper GI bleeding

Review: SSRI use ups risk of upper GI bleeding

(HealthDay)—Selective serotonin reuptake inhibitor (SSRI) use is associated with increased risk of upper gastrointestinal bleeding (UGIB), according to a meta-analysis published in the January issue of Clinical Gastroenterology and Hepatology.

Hai-Yin Jiang, from Zhejiang University in Hangzhou, China, and colleagues conducted a and meta-analysis of controlled observational studies to examine whether SSRI use impacts the risk of UGIB. Data were included for 22 studies (six cohort and 16 case-control) involving more than 1,073,000 individuals.

The researchers found that the odds for developing UGIB were 1.55 fold-higher for SSRI users versus patients who had not taken SSRIs. Subgroup analysis indicated that the correlation was strongest for patients who received concurrent therapy with nonsteroidal anti-inflammatory or . Among patients receiving concurrent acid-suppressing drugs, there was no significant increase of developing UGIB.

"SSRI use was associated with an almost two-fold increase in the risk of developing UGIB, especially among patients at high risk for GI bleeding (concurrent use of nonsteroidal anti-inflammatory or antiplatelet drugs)," the authors write. "This risk might be reduced significantly by concomitant use of acid-suppressing drugs."

Explore further

Increased risk of bleeding with combined use of SSRIs and antiplatelet therapy after heart attacks

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Review: SSRI use ups risk of upper GI bleeding (2015, January 5) retrieved 18 January 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors